MREO · Mereo BioPharma Group plc

Track MREO — free

$0.30 +0.00 (+1.12%)

Rebalance outlook locked

Market Cap

$47.12M

159.69M

Volume · Oct 21 62.64K Avg daily vol (3M) 4M

Up next

Next earnings call

Oct 23, 2026 Est · unconfirmed · this week

Latest filing: 10-Q

filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$28.10M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

-8,021.4%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-52.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$30.12M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.5%

Year over year · more shares

Price change (1Y)

-86.8%

Trailing year

Short interest

1.7%

Latest settlement · 1.3 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

· $1.00M −$9.11M '23 Q4* · $0 −$8.95M '24 Q1 ▼100% $0 −$12.26M '24 Q2 · $0 −$15.00M '24 Q3 ▼100% $0 −$7.05M '24 Q4* · $500,000 −$14.62M '25 Q2 · $0 −$7.02M '25 Q3 LATEST ▼100% $0 −$7.00M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 17.3 · elevated Equity put/call 0.56

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −14%

below

Price vs 50-day avg −4%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 3%

near low

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Weak

1-month return −7%

trailing

6-month return +7%

trailing

YTD return −29%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $0 › 200d $0 — 200d above 50d

Institutional flow Distributing

2 of 60 funds reported for Sep 30 · net -7.3K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

1.68% of float · ▼ -12.9% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

60 holders — mid 3-yr range

Squeeze score 43

elevated · 0–100

Fundamentals

Strong

EPS growth +17%

Y/Y

Free cash flow $-31.0M

Balance sheet $41.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 132%

annualized · 1-yr

Max drawdown −90%

past year

ATR 10.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−14% Bearish

Price vs 50-day avg

−4% Neutral

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

3% Bearish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $0 › 200d $0 — 200d above 50d

Institutional flow Distributing

2 of 60 funds reported for Sep 30 · net -7.3K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

1.68% of float · ▼ -12.9% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

60 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $0 Now $0 · 3% Range high $2

vs 200-day avg -14% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Total ADS equivalents	159,618,608	As of June 30, 2026	—
Total ordinary shares issued	798,093,044	As of June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MREO Mereo BioPharma Group plc this stock	$47.12M	-29.2%	—	—	1.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$131.39B	+13.5%	+46.2%	30.2	1.8%
MRNA Moderna, Inc.	$96.65B	+720.9%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$83.13B	+4.6%	+20.8%	20.0	2.1%
CSLLY Csl Ltd	$66.34B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 35.9%
Reported: 2 of 60
Top holder: Rubric Capital Management…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.7M

Days to cover: 1.3d
Change: -397.5K sh

View

Short Volume

Short vol %

46%

As of: Oct 20, 2026

Short Total

View

Fails to Deliver

FTD shares

35.6K

Value: $13.2K
As of: Sep 30, 2026

View

Off-Exchange

Off-exchange %

54.8%

Week of: Sep 14, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$500.0K

Net income (FY): $-41.9M
EPS diluted: $-0.05

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 19, 2026
This year: 15

View

Proposed Sales

Value

$75.3K

Shares: 16.1K
Filed: Sep 12, 2024

View

Exempt Offerings

Offering

$70.0M

Filed: Jun 12, 2020

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MREO	-7.8%	-6.7%	+6.9%	-26.6%	-29.2%
SPY	-1.2%	-0.6%	+8.1%	+0.8%	+12.8%
vs SPY	-6.6%	-6.1%	-1.2%	-27.4%	-42.0%

Key facts CIK 1719714 CUSIP 589492107 13F (30d) 3 filings 3 filers Visit website Investor relations

MREO · Mereo BioPharma Group plc

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance